标题
Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer
作者
关键词
-
出版物
MOLECULES
Volume 27, Issue 12, Pages 3798
出版商
MDPI AG
发表日期
2022-06-14
DOI
10.3390/molecules27123798
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Immune-related adverse events and the balancing act of immunotherapy
- (2022) Michael Conroy et al. Nature Communications
- Autophagy as a Therapeutic Target of Natural Products Enhancing Embryo Implantation
- (2022) Hyerin Park et al. Pharmaceuticals
- Stem Cell Transplantation Therapy and Neurological Disorders: Current Status and Future Perspectives
- (2022) Md. Rahman et al. Biology-Basel
- Natural therapeutics and nutraceuticals for lung diseases: Traditional significance, phytochemistry, and pharmacology
- (2022) Md. Mominur Rahman et al. BIOMEDICINE & PHARMACOTHERAPY
- Multifunctional Therapeutic Approach of Nanomedicines against Inflammation in Cancer and Aging
- (2022) Md. Mominur Rahman et al. Journal of Nanomaterials
- B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome
- (2022) Wolf H. Fridman et al. Nature Reviews Clinical Oncology
- Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy
- (2022) T. Anders Olsen et al. Frontiers in Endocrinology
- Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review
- (2021) Josefien W. Hommes et al. Frontiers in Oncology
- Recognizing the Benefits of Pre-/Probiotics in Metabolic Syndrome and Type 2 Diabetes Mellitus Considering the Influence of Akkermansia muciniphila as a Key Gut Bacterium
- (2021) Raluca Anca Corb Aron et al. Microorganisms
- Precision oncology: a clinical and patient perspective
- (2021) Ulrik N Lassen et al. Future Oncology
- Immune‐Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
- (2021) Dylan J. Martini et al. ONCOLOGIST
- Are Markers of Systemic Inflammatory Response Useful in the Management of Patients With Neuroendocrine Neoplasms?
- (2021) Elisa Giannetta et al. Frontiers in Endocrinology
- Current Perspective on the Natural Compounds and Drug Delivery Techniques in Glioblastoma Multiforme
- (2021) Tapan Behl et al. Cancers
- Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
- (2021) Bianca D. Santomasso et al. JOURNAL OF CLINICAL ONCOLOGY
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
- (2021) Bryan J. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events
- (2021) Jia Luo et al. Journal of Thoracic Oncology
- Berberine as a Potential Anticancer Agent: A Comprehensive Review
- (2021) Abdur Rauf et al. MOLECULES
- Immune‐Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration‐Approved Indications for Immunotherapy
- (2020) Satya Das et al. ONCOLOGIST
- iRECIST: how to do it
- (2020) Thorsten Persigehl et al. CANCER IMAGING
- Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions
- (2020) Malek Kreidieh et al. Biomed Research International
- Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
- (2020) Manuela Tiako Meyo et al. Cancers
- Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients
- (2020) Jesus Vera Aguilera et al. MELANOMA RESEARCH
- Immune-related adverse events of checkpoint inhibitors
- (2020) Manuel Ramos-Casals et al. Nature Reviews Disease Primers
- Warburg and Beyond: The Power of Mitochondrial Metabolism to Collaborate or Replace Fermentative Glycolysis in Cancer
- (2020) Shamir Cassim et al. Cancers
- Immunothérapie des cancers bronchiques non à petites cellules métastatiques, de la première ligne à la résistance et sa prise en charge
- (2020) Clémence Basse et al. BULLETIN DU CANCER
- The non-invasive assessment of hepatic fibrosis
- (2020) Gina Gheorghe et al. JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
- Strategies for improving the management of immune-related adverse events
- (2020) Aung Naing et al. Journal for ImmunoTherapy of Cancer
- Current advancements and future perspectives of immunotherapy in colorectal cancer research
- (2020) Chandra Kishore et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Immune checkpoint blockade for Merkel cell carcinoma: actual findings and unanswered questions
- (2019) Marco Gallo et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- New therapeutic perspectives to manage refractory immune checkpoint-related toxicities
- (2019) Filipe Martins et al. LANCET ONCOLOGY
- Immune checkpoint inhibitor-induced colitis: A comprehensive review
- (2019) Aniruddh Som et al. World Journal of Clinical Cases
- Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
- (2019) John A. Thompson et al. Journal of the National Comprehensive Cancer Network
- Management of immune related adverse events induced by immune checkpoint inhibition
- (2019) Andreas Teufel et al. CANCER LETTERS
- Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells
- (2019) T. Alissafi et al. JOURNAL OF AUTOIMMUNITY
- BP180-specific IgG is associated with skin adverse events, therapy response and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors
- (2019) Omar Hasan Ali et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
- (2019) Robert J Motzer et al. LANCET ONCOLOGY
- Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors
- (2019) Sophia C Weinmann et al. RHEUMATOLOGY
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- New insight in endocrine-related adverse events associated to immune checkpoint blockade
- (2019) Giusy Elia et al. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy
- (2019) Yi-He Liu et al. BIOMEDICINE & PHARMACOTHERAPY
- Tumor Microenvironment: A Metabolic Player that Shapes the Immune Response
- (2019) Shamir Cassim et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA
- (2018) Sarah B. Goldberg et al. CLINICAL CANCER RESEARCH
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
- (2018) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists’ perspective
- (2018) Dipti M Karamchandani et al. JOURNAL OF CLINICAL PATHOLOGY
- Scleroderma-like skin changes induced by checkpoint inhibitor therapy
- (2018) B. Joel Tjarks et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors
- (2018) Eleonora De Martin et al. JOURNAL OF HEPATOLOGY
- International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
- (2018) Franck Pagès et al. LANCET
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
- (2018) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Case of Nivolumab‐Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein‐1/Programmed Death Ligand‐1 Inhibitors and Recommendations for Diagnosis and Management
- (2018) Adriana T. Lopez et al. ONCOLOGIST
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
- (2018) Shrujal Baxi et al. BMJ-British Medical Journal
- Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
- (2018) Judith A. Seidel et al. Frontiers in Oncology
- Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1
- (2018) Andrew L Mammen et al. ANNALS OF THE RHEUMATIC DISEASES
- Activity of targeted therapy after failure of first-line immunotherapy in BRAF-mutant metastatic melanoma.
- (2018) Cathy Yi Xia et al. JOURNAL OF CLINICAL ONCOLOGY
- Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)
- (2018) Elizabeth Dudnik et al. LUNG CANCER
- Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer
- (2018) Muhammad Khan et al. MEDICINE
- Rheumatic immune-related adverse events from cancer immunotherapy
- (2018) Leonard H. Calabrese et al. Nature Reviews Rheumatology
- Immune-Related Adverse Events in Cancer Patients Treated With Immune Checkpoint Inhibitors
- (2018) Sabina Sandigursky et al. Current Rheumatology Reports
- Immune Checkpoint Inhibitor-Associated Colits and Hepatitis
- (2018) Haritha G. Reddy et al. Clinical and Translational Gastroenterology
- A whole-blood RNA transcript-based gene signature is associated with the development of CTLA-4 blockade-related diarrhea in patients with advanced melanoma treated with the checkpoint inhibitor tremelimumab
- (2018) Philip Friedlander et al. Journal for ImmunoTherapy of Cancer
- Tildrakizumab: A Review of Phase II and III Clinical Trials
- (2018) Sree S. Kolli et al. ANNALS OF PHARMACOTHERAPY
- Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
- (2018) Juliane Gust et al. CNS DRUGS
- Immune-related adverse events of immune checkpoint inhibitors: a brief review
- (2018) G. Myers Current Oncology
- Tisagenlecleucel-T for the treatment of acute lymphocytic leukemia
- (2018) Xavier Thomas et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma
- (2018) Michael J Flynn et al. HEPATOLOGY
- Induced CD20 expression on B-cell malignant cells heightened the cytotoxic activity of chimeric antigen receptor engineered T cells
- (2018) Yingxi Xu et al. HUMAN GENE THERAPY
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Cases from the irAE Tumor Board: A Multidisciplinary Approach to a Patient Treated with Immune Checkpoint Blockade Who Presented with a New Rash
- (2018) Pradnya D. Patil et al. ONCOLOGIST
- The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma
- (2017) Emma S Scott et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia
- (2017) Jun Liu et al. Immunotherapy
- Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience
- (2017) Takeo Fujii et al. INVESTIGATIONAL NEW DRUGS
- Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
- (2017) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy
- (2017) Cynthia L. Gay et al. JOURNAL OF INFECTIOUS DISEASES
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Risk of Pneumonitis Associated with Programmed Cell Death 1 Inhibitors in Cancer Patients: A Meta-analysis
- (2017) Sheng Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Is autoimmunity the Achilles' heel of cancer immunotherapy?
- (2017) Carl H June et al. NATURE MEDICINE
- Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies
- (2017) David J. Byun et al. Nature Reviews Endocrinology
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Immune‑related adverse events during anticancer immunotherapy: Pathogenesis and management (Review)
- (2017) Stefania Stucci et al. Oncology Letters
- Excellent response to chemotherapy post immunotherapy
- (2017) Ashish D. Dwary et al. Oncotarget
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients
- (2017) Guillermo De Velasco et al. Cancer Immunology Research
- Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
- (2017) Vivek Kumar et al. Frontiers in Pharmacology
- Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group
- (2017) I. Puzanov et al. Journal for ImmunoTherapy of Cancer
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer
- (2016) J.C. Osorio et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
- (2016) Thomas K. Eigentler et al. CANCER TREATMENT REVIEWS
- Management of toxicities of immune checkpoint inhibitors
- (2016) Lavinia Spain et al. CANCER TREATMENT REVIEWS
- Immune-mediated respiratory adverse events of checkpoint inhibitors
- (2016) Samer Tabchi et al. CURRENT OPINION IN ONCOLOGY
- Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis
- (2016) Omar Abdel-Rahman et al. Future Oncology
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Surrogate End Points and Their Validation in Oncology Clinical Trials
- (2016) Fengmin Zhao JOURNAL OF CLINICAL ONCOLOGY
- Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
- (2016) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease
- (2016) L. Marthey et al. Journal of Crohns & Colitis
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
- (2016) Paul T. Nghiem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
- (2016) Vassiliki A. Boussiotis NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events
- (2016) Elisa González-Rodríguez et al. ONCOLOGIST
- Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management
- (2016) Paola Savoia et al. Human Vaccines & Immunotherapeutics
- Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients
- (2016) Yumi Nonomura et al. OncoImmunology
- Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update
- (2016) Masatoshi Kudo Liver Cancer
- Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors
- (2016) Claire F. Friedman et al. JAMA Oncology
- Ipilimumab-associated Hepatitis
- (2015) Melanie Johncilla et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors
- (2015) T. W. Chen et al. ANNALS OF ONCOLOGY
- Genetic analysis reveals diversity and genetic relationship among Trichoderma isolates from potting media, cultivated soil and uncultivated soil
- (2015) Abdullah M. Al-Sadi et al. BMC MICROBIOLOGY
- Infliximab for IPILIMUMAB-Related Colitis--Letter
- (2015) E. Arriola et al. CLINICAL CANCER RESEARCH
- Cancer immunotherapy: harnessing the immune system to battle cancer
- (2015) Yiping Yang JOURNAL OF CLINICAL INVESTIGATION
- Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
- (2015) Hansje-Eva Teulings et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer
- (2015) Junzo Hamanishi et al. JOURNAL OF CLINICAL ONCOLOGY
- The place of PD-1 inhibitors in melanoma management
- (2015) Samantha Bowyer et al. LANCET ONCOLOGY
- Releasing the Brakes on Cancer Immunotherapy
- (2015) Antoni Ribas NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy
- (2015) Ninh M. La-Beck et al. PHARMACOTHERAPY
- Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab
- (2015) S. H. Tirumani et al. Cancer Immunology Research
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution
- (2014) Mabel Ryder et al. ENDOCRINE-RELATED CANCER
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses
- (2013) Francesco Torino et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
- (2013) Salvatore Maria Corsello et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Continued Response Off Treatment After BRAF Inhibition in Refractory Hairy Cell Leukemia
- (2013) Sascha Dietrich et al. JOURNAL OF CLINICAL ONCOLOGY
- Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
- (2013) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events
- (2013) Vafa Shahabi et al. Journal of Translational Medicine
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
- (2013) Charles Butts et al. LANCET ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natural Innate and Adaptive Immunity to Cancer
- (2011) Matthew D. Vesely et al. Annual Review of Immunology
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review
- (2010) Katsuhiko Nosho et al. JOURNAL OF PATHOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- (2009) J. Weber et al. CLINICAL CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
- (2009) Troy Dillard et al. Pituitary
- Survival for Patients With Invasive Cutaneous Melanoma Among Ethnic Groups: The Effects of Socioeconomic Status and Treatment
- (2007) Jason A. Zell et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation